Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Changes in bone turnover during tibolone treatment.

Gregorio Riera-Espinoza1, Jenny Ramos, Rosalía Carvajal

  • 1UNILIME, Universidad de Carabobo, Hospital Universitario Dr. Angel Larralde, IVSS, Valencia, Venezuela. griera@net-uno.net

Maturitas
|February 6, 2004
PubMed
Summary

Tibolone treatment in postmenopausal women significantly reduced bone resorption and formation markers over one year. Bone mineral density was maintained, indicating a positive effect on bone remodeling.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Female orgasmic dysfunction and severe climacteric symptomatology in women aged 40 to 59 years: an independent association from an analysis of a multicenter Latin American study.

Menopause (New York, N.Y.)·2022
Same author

Menopause could be involved in the pathogenesis of muscle and joint aches in mid-aged women.

Maturitas·2013
Same author

A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women.

Menopause (New York, N.Y.)·2011
Same author

Sexual dysfunction in middle-aged women: a multicenter Latin American study using the Female Sexual Function Index.

Menopause (New York, N.Y.)·2009
Same author

Epidemiology of osteoporosis in Latin America 2008.

Salud publica de Mexico·2009
Same author

Impaired quality of life among middle aged women: a multicentre Latin American study.

Maturitas·2008

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Menopause is associated with increased bone turnover and risk of osteoporosis.
  • Tibolone is a synthetic steroid used for hormone replacement therapy in postmenopausal women.
  • Understanding tibolone's effects on bone remodeling markers is crucial for managing menopausal bone health.

Purpose of the Study:

  • To evaluate the impact of continuous tibolone treatment on bone remodeling markers.
  • To assess changes in N-telopeptide (NTx), tartrate-resistant acid phosphatase (TRAP), total alkaline phosphatase (TAP), and bone alkaline phosphatase (BAP) over 12 months.

Main Methods:

  • An open study involving 36 postmenopausal women.
  • Daily administration of tibolone 2.5 mg for 1 year.

Related Experiment Videos

  • Biochemical markers of bone metabolism and densitometry were measured at baseline and at 1, 3, 6, and 12 months.

    • Main Results:

    • Significant decreases in bone alkaline phosphatase (BAP) and all resorption markers (NTx, TRAP) were observed by 12 months.
    • NTx levels decreased from the start of treatment.
    • Bone mineral density at the forearm remained stable throughout the study period.

    Conclusions:

    • Tibolone 2.5 mg daily effectively reduced bone resorption and formation markers in postmenopausal women.
    • The treatment demonstrated a sustained positive effect on bone turnover over 1 year.
    • Tibolone appears to be a beneficial option for managing bone metabolism during postmenopause.